Research & Publications †
( † Disclaimer: This search is powered by PubMed, a service of the U.S. National Library of Medicine. PubMed is a third-party website with no affiliation with Cleveland Clinic.)
Robert Dean, MD, joined the Staff of the Cleveland Clinic Taussig Cancer Institute in 2005. Dr. Dean attended undergraduate and medical school at the University of Pennsylvania. He received his internal medicine training at Boston University Medical Center and studied primary amyloidosis while serving as a research fellow there. Dr. Dean then pursued fellowship training in medical oncology and hematology at the National Cancer Institute of the National Institutes of Health, where he also conducted research in allogeneic stem cell transplantation.
As a member of the Department of Hematologic Oncology and Blood Disorders, Dr. Dean treats patients with lymphoma, multiple myeloma, amyloidosis and leukemia. He is board-certified in internal medicine, medical oncology and hematology. Dr. Dean attends on the inpatient Bone Marrow Transplantation Service and the Leukemia Service at Cleveland Clinic.
His professional memberships include the American College of Physicians, American Society of Hematology, American Society of Clinical Oncology and American Society for Blood and Marrow Transplantation.
Dr. Dean's current research focuses upon bone marrow and stem cell transplantation for lymphomas and other hematologic diseases, as well as novel treatment approaches for lymphomas and multiple myeloma. He has published multiple research articles in these areas, and he regularly presents new research at national and international scientific meetings.
Bone marrow and stem cell transplantation, lymphoma, leukemia, multiple myeloma, amyloid light-chain (AL) amyloidosis, cancer, bone marrow transplant, stem cell transplant
Awards & Honors
Fellow in FACP since 7/1/09 from the Ohio Chapter
Cleveland Clinic physicians and scientists may collaborate with the pharmaceutical or medical device industries to help develop medical breakthroughs or provide medical expertise or education. Cleveland Clinic strives to make scientific advances that will benefit patient care and support outside relationships that promise public benefit. In order for the discoveries of Cleveland Clinic physicians' and scientists' laboratories and investigations to benefit the public, these discoveries must be commercialized in partnership with industry. As experts in their fields, Cleveland Clinic physicians and scientists are often sought after by industry to consult, provide expertise and education.
To assure professional and commercial integrity in such matters, Cleveland Clinic maintains a program that reviews these collaborations and, when appropriate, puts measures in place to minimize bias that may result from ties to industry. The Cleveland Clinic publicly discloses the names of companies when (i) its physicians/scientists receive $5,000 or more per year (or, in rare cases, equity or stock options) for speaking and consulting, (ii) its physicians/scientists serve as a fiduciary, (iii) its physicians/scientists
receive or have the right to receive royalties or (iv) its physicians/scientists hold any equity interest for the physician's/scientist's role as inventor, discoverer, developer, founder or consultant.* In publicly disclosing this information, the Cleveland Clinic tries to provide information as accurately as possible about its physicians' and scientists' connections with industry.
As of 3/4/2015, Dr. Dean has reported no financial relationship with industry that is applicable to this listing. In general, patients should feel free to contact their doctor about any of the relationships and how the relationships are overseen by the Cleveland Clinic. To learn more about the Cleveland Clinic's policies on collaborations with industry and innovation management, go to our Integrity in Innovation page.
Public Health Service-Reportable Financial Conflicts of Interest. Cleveland Clinic scientists and physicians engage in basic, translational and clinical research activities, working to solve health problems, enhance patient care and improve quality of life for patients. Interactions with industry are essential to bringing the researchers’ discoveries to the public, but can present the potential for conflicts of interest related to their research activities. Click here to view a listing of instances where Cleveland Clinic has identified a Public Health Service (PHS)-Reportable Financial Conflict of Interest and has put measures in place to ensure that, to the extent possible, the design, conduct and reporting of the research is free from bias. * Cleveland Clinic physicians and scientists subscribe to the guidance presented in the PhRMA Code on Interactions with Healthcare Professionals and the AdvaMed Code of Ethics on Interactions with Health Care Professionals. As such, gifts of substantial value are generally prohibited.